Search Result

Results for "

insulin secretion

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Insulin Receptor (10) Acyltransferase (1) Adrenergic Receptor (1) Akt (2) Amylin Receptor (5) Apoptosis (6) Autophagy (1) Biochemical Assay Reagents (1) Calcium Channel (2) CGRP Receptor (1) CRFR (1) DYRK (2) Endogenous Metabolite (2) ERK (2) Free Fatty Acid Receptor (12) GCGR (11) GLP Receptor (3) Glucocorticoid Receptor (2) Glucokinase (2) GLUT (1) GnRH Receptor (1) GPR119 (1) Influenza Virus (1) mAChR (1) Neuropeptide Y Receptor (1) NF-κB (1) p38 MAPK (2) Parasite (2) PARP (1) Phosphatase (2) Phospholipase (1) PKA (2) Potassium Channel (1) PPAR (4) Proton Pump (1) PTEN (2) Reactive Oxygen Species (3) Somatostatin Receptor (1) Taste Receptor (1) Trace Amine-associated Receptor (TAAR) (1) TRP Channel (1)
By Research Areas:	Cancer (4) Cardiovascular Disease (7) Endocrinology (6) Infection (3) Inflammation/Immunology (6) Metabolic Disease (73) Neurological Disease (8)

By Targets:

Insulin Receptor (10)

Acyltransferase (1)

Adrenergic Receptor (1)

Akt (2)

Amylin Receptor (5)

Apoptosis (6)

Autophagy (1)

Biochemical Assay Reagents (1)

Calcium Channel (2)

CGRP Receptor (1)

CRFR (1)

DYRK (2)

Endogenous Metabolite (2)

ERK (2)

Free Fatty Acid Receptor (12)

GCGR (11)

GLP Receptor (3)

Glucocorticoid Receptor (2)

Glucokinase (2)

GLUT (1)

GnRH Receptor (1)

GPR119 (1)

Influenza Virus (1)

mAChR (1)

Neuropeptide Y Receptor (1)

NF-κB (1)

p38 MAPK (2)

Parasite (2)

PARP (1)

Phosphatase (2)

Phospholipase (1)

PKA (2)

Potassium Channel (1)

PPAR (4)

Proton Pump (1)

PTEN (2)

Reactive Oxygen Species (3)

Somatostatin Receptor (1)

Taste Receptor (1)

Trace Amine-associated Receptor (TAAR) (1)

TRP Channel (1)

By Research Areas:

Cancer (4)

Cardiovascular Disease (7)

Endocrinology (6)

Infection (3)

Inflammation/Immunology (6)

Metabolic Disease (73)

Neurological Disease (8)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Targets Recommended: Insulin Receptor IGF-1R

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-157189

GPR132 antagonist 1	Others	Metabolic Disease
GPR132 antagonist 1 (GPR132-B-160, Compound 25) is a GPR132 antagonist with an EC₅₀ value of 0.075 μM. GPR132 antagonist 1 has promote insulin secretion activity with an EC₅₀ value of 0.7 μM .

HY-107651

VU 0365114 1 Publications Verification	mAChR	Metabolic Disease
VU 0365114 is a selective mAChR M₅ positive allosteric modulator, with an EC₅₀ of 2.7 μM, and >30 μM for M1, M2, M3 and M4 receptors. VU 0365114 increases insulin secretion stimulated by ACh in human β-cells .

HY-163294

PPARγ agonist 10	PPAR	Metabolic Disease
PPARγ agonist 10 (compound 33g) is a PPARγ agonist, and stimulats the insulin secretion, glucose uptake and insulin Sensitivity in βTC6 Cells .

HY-157189A

GPR132 antagonist 1 (dihydrocholide)	Others	Metabolic Disease
GPR132 antagonist 1 dihydrocholide (GPR132-B-160, Compound 25) is a GPR132 antagonist with an EC₅₀ value of 0.075 μM. GPR132 antagonist 1 dihydrocholide has promote insulin secretion activity with an EC₅₀ value of 0.7 μM .

HY-P1124

AS2034178 free base	Free Fatty Acid Receptor	Metabolic Disease
AS2034178 free base, a specific and orally active GPR40 agonist, exhibits glucose-dependent insulin secretion enhancement. AS2034178 free base has potential for type 2 diabetes mellitus research .

HY-P1871A

Amylin (IAPP), feline TFA	Amylin Receptor	Metabolic Disease
Amylin (IAPP), feline TFA is a 37-amino acid polypeptide from feline. Amylin (IAPP), feline TFA is one of the major secretory products of β-cells of the pancreatic islets. Amylin (IAPP), feline TFA is a regulatory peptide, which inhibits insulin and glucagon secretion .

HY-P1871

Amylin (IAPP), feline	Amylin Receptor	Metabolic Disease
Amylin (IAPP), feline is a 37-amino acid polypeptide from feline. Amylin (IAPP), feline is one of the major secretory products of β-cells of the pancreatic islets. Amylin (IAPP), feline is a regulatory peptide, which inhibits insulin and glucagon secretion .

HY-107535

AS1269574	GPR119 TRP Channel	Metabolic Disease
AS1269574 is a potent, orally available GPR119 agonist, with an EC₅₀ of 2.5 μM in HEK293 cells expressing human GPR119. AS1269574 activates TRPA1 cation channels to stimulate glucagon-like peptide-1 (GLP-1) secretion. AS1269574 specifically induces glucose-dependent insulin secretion from pancreatic β-cells only under high-glucose conditions. AS1269574 has the potential for the research of type 2 diabetes .

HY-15671

GKA50	Glucokinase	Metabolic Disease
GKA50 is a potent glucokinase activator (EC₅₀=33 nM at 5 mM glucose). GKA50 stimulates insulin release from mouse islets of Langerhans. GKA50 is a glucose-like activator of beta-cell metabolism in rodent and human islets and a Ca ²⁺-dependent modulator of insulin secretion. GKA50 shows significant glucose lowering in high fat fed female rats .

HY-15671A

GKA50 quarterhydrate	Glucokinase	Metabolic Disease
GKA50 quarterhydrate is a potent glucokinase activator (EC₅₀=33 nM at 5 mM glucose) and stimulates insulin release from mouse islets of Langerhans. GKA50 quarterhydrate is a glucose-like activator of beta-cell metabolism in rodent and human islets and a Ca ²⁺-dependent modulator of insulin secretion. GKA50 quarterhydrate shows significant glucose lowering in high fat fed female rats .

HY-108611

AACOCF3 2 Publications Verification Arachidonyl trifluoromethyl ketone	Phospholipase	Cardiovascular Disease
AACOCF3 (Arachidonyl trifluoromethyl ketone) is a cell-permeant trifluoromethyl ketone analog of arachidonic acid. AACOCF3 is a potent and selective slow binding inhibitor of the 85-kDa cytosolic phospholipase A2 (cPLA2). AACOCF3 blocks production of arachidonate and 12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets. AACOCF3 inhibits glucose-induced insulin secretion from isolated rat islets. AACOCF3 has the potential for the research of cardiovascular disease .

HY-14363

TUG-424	Free Fatty Acid Receptor	Metabolic Disease
TUG-424 is a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with an EC₅₀ of 32 nM. TUG-424 significantly increases glucose-stimulated insulin secretion at 100 nM. TUG-424 may serve to explore the role of FFA1 in metabolic diseases such as diabetes or obesity . TUG-424 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-142295

GNF2133	DYRK	Metabolic Disease
GNF2133 is a potent, selective and orally active DYRK1A inhibitor with IC₅₀s of 0.0062, >50 µM for DYRK1A and GSK3β, respectively. GNF2133 shows good proliferation potency and efficacy on rat and human primary β-cell. GNF2133 significantly improves glucose disposal capacity and increases insulin secretion. GNF2133 has the potential for the research of type 1 diabetes .

HY-142295A

GNF2133 hydrochloride	DYRK	Metabolic Disease
GNF2133 hydrochloride is a potent, selective and orally active DYRK1A inhibitor with IC₅₀s of 0.0062, >50 µM for DYRK1A and GSK3β, respectively. GNF2133 hydrochloride shows good proliferation potency and efficacy on rat and human primary β-cell. GNF2133 hydrochloride significantly improves glucose disposal capacity and increases insulin secretion. GNF2133 hydrochloride has the potential for the research of type 1 diabetes .

HY-19995

GSK137647A 1 Publications Verification GSK 137647	Free Fatty Acid Receptor	Metabolic Disease
GSK137647A (GSK 137647) is a potent, selective free fatty acid receptor 4 (FFA4) agonist with pEC₅₀ values of 6.3, 6.2, and 6.1 for human, mouse and rat FFA4, and pEC₅₀ values < 4.5 for all three species for FFA1, FFA2, and FFA3, respectively. GSK137647A has anti-inflammatory activity. GSK137647A induces insulin secretion and inhibits epithelial ion transport, GSK137647A is related to regulation of glucose homeostasis and anti-inflammatory response .

HY-117656

ESI-05 3 Publications Verification NSC 116966	Acyltransferase	Neurological Disease Metabolic Disease
ESI-05 is a specific exchange proteins directly activated by cAMP 2 (EPAC2) inhibitor. ESI-05 inhibits cAMP-mediated EPAC2 GEF activity with an IC₅₀ of 0.43 μM. ESI-05 can be used for the research of diabetes, insulin secretion and neurological disorders .

HY-B1021

Vincamine	Free Fatty Acid Receptor	Cardiovascular Disease Metabolic Disease
Vincamine is a monoterpenoid indole alkaloid extracted from the Madagascar periwinkle. Vincamine is a peripheral vasodilator and exerts a selective vasoregulator action on the brain microcapilar circulation . Vincamine is a GPR40 agonist and acts as a β-cell protector by ameliorating β-cell dysfunction and promoting glucose-stimulated insulin secretion (GSIS). Vincamine improves glucose homeostasis in vivo, and has the potential for the type 2 diabetes mellitus (T2DM) research .

HY-P0150

Glucagon (19-29), human

GCGR Neurological Disease

Glucagon (19-29), human is a potent and efficient inhibitor of insulin secretion.

Glucagon (19-29), human	GCGR	Neurological Disease
Glucagon (19-29), human is a potent and efficient inhibitor of insulin secretion.

HY-P0054A

GLP-1(7-36), amide Glucagon-like peptide-1 (GLP-1)(7-36), amide; Human GLP-1 (7-36), amide	GCGR	Metabolic Disease
GLP-1(7-36), amide is a physiological incretin hormone that stimulates insulin secretion.

HY-P2080

GIP (1-30) amide,human	Insulin Receptor	Metabolic Disease
GIP (1-30) amide,human is a glucose-dependent insulinotropic polypeptide (GIP) fragment. GIP is an incretin hormone that stimulates insulin secretion and reduces postprandial glycaemic excursions. GIP (1-30) amide,human dose-dependently promotes insulin secretion over the range 10 ^-9-10 ^-6 M .

HY-P2080B

GIP (1-30) amide,human acetate	Insulin Receptor	Metabolic Disease
GIP (1-30) amide,human acetate is a glucose-dependent insulinotropic polypeptide (GIP) fragment. GIP is an incretin hormone that stimulates insulin secretion and reduces postprandial glycaemic excursions. GIP (1-30) amide,human acetate dose-dependently promotes insulin secretion over the range 10 ^-9-10 ^-6 M .

HY-P0055

GLP-1(7-37)

3 Publications Verification

GCGR Metabolic Disease

GLP-1(7-37) is an intestinal insulinotropic hormone that augments glucose induced insulin secretion.

GLP-1(7-37) 3 Publications Verification	GCGR	Metabolic Disease
GLP-1(7-37) is an intestinal insulinotropic hormone that augments glucose induced insulin secretion.

HY-P0055A

GLP-1(7-37) acetate 3 Publications Verification	GCGR	Metabolic Disease
GLP-1(7-37) acetate is an intestinal insulinotropic hormone that augments glucose induced insulin secretion .

HY-P2080C

GIP (1-30)-Myr	Insulin Receptor	Metabolic Disease
GIP (1-30)-Myr is the Myr-modified GIP (1-30), which is a glucose-dependent insulinotropic polypeptide (GIP) fragment. GIP is an incretin hormone that stimulates insulin secretion and reduces postprandial glycaemic excursions. GIP (1-30) dose-dependently promotes insulin secretion over the range 10 ^-9-10 ^-6 M .

HY-P5074

GRPP (human)	GCGR	Metabolic Disease
GRPP (human) is a 30 amino acid Gcg-derived peptide. GRPP (human) causes slight increases in plasma insulin and decreases in plasma glucagon. GRPP (human) does not affect insulin secretion in rat islets .

HY-139709

Glucocorticoids receptor agonist 1	Glucocorticoid Receptor	Inflammation/Immunology
Glucocorticoids receptor agonist 1 is a potent anti-inflammatory, arylpyrazole-based glucocorticoid receptor agonist that does not impair insulin secretion.

HY-139710

Glucocorticoids receptor agonist 2	Glucocorticoid Receptor	Inflammation/Immunology
Glucocorticoids receptor agonist 2 is a potent anti-inflammatory, arylpyrazole-based glucocorticoid receptor agonist that does not impair insulin secretion.

HY-P0054

GLP-1(7-36), amide acetate 5+ Cited Publications Glucagon-like peptide-1 (GLP-1)(7-36), amide acetate; Human GLP-1 (7-36), amide acetate	GCGR	Metabolic Disease
GLP-1(7-36), amide acetate is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.

HY-109556

Insulin Detemir	Akt ERK	Metabolic Disease
Insulin Detemir is an artificial insulin, shows effect on controlling blood sugar levels. Insulin Detemir stimulates GLP-1 secretion as a consequence of enhanced Gcg expression by a mechanism involving activation of Akt- and/or extracellular signal-regulated kinase (ERK)-dependent-cat and CREB signaling pathways. Insulin Detemir can be used for type 2 diabetes research .

HY-107544

8-pCPT-2'-O-Me-cAMP-AM	PKA	Metabolic Disease
8-pCPT-2'-O-Me-cAMP-AM is a cyclic AMP analogue, selectively activates Epac-Rap signaling pathway. 8-pCPT-2'-O-Me-cAMP-AM protects renal function by activating Epac from ischemia injury. 8-pCPT-2'-O-Me-cAMP-AM also stimulates insulin secretion by interaction with PKA pathway .

HY-P10062

Hylambatin	Biochemical Assay Reagents	Metabolic Disease
Hylambatin, a tachykinin, increases both plasma glucose and plasma insulin, whereas the secretion of glucagon was not affected. Hylambatin can be used in diabetes research .

HY-P0054B

GLP-1(7-36), amide TFA 5+ Cited Publications Glucagon-like peptide-1 (GLP-1)(7-36), amide TFA; Human GLP-1 (7-36), amide TFA	GCGR	Metabolic Disease
GLP-1(7-36), amide TFA is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells .

HY-N8839

Momordicine II	Others	Others
Momordicine II significantly stimulated insulin secretion that may have antidiabetic activity. Momordicine II also can deter oviposition by L. trifolii significantly .

HY-143401

Hit 1

Others Metabolic Disease

Hit 1 is an activator of ansulin degrading enzyme (IDE), with an EC₅₀ of 5.5 μM. Hit 1 can decrease glucose-stimulating insulin secretion .

Hit 1	Others	Metabolic Disease
Hit 1 is an activator of ansulin degrading enzyme (IDE), with an EC₅₀ of 5.5 μM. Hit 1 can decrease glucose-stimulating insulin secretion .

HY-P0276

GIP, human 1 Publications Verification Gastric Inhibitory Peptide (GIP), human	Insulin Receptor	Metabolic Disease
GIP, human, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP, human acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion .

HY-P3954

Somatostatin-28 (sheep, human rat mouse)	Somatostatin Receptor	Metabolic Disease
Somatostatin-28 (sheep, human rat mouse) is a biologically active polypeptide, synthesised in the proximal intestinal epithelial cells. Somatostatin-28 (sheep, human rat mouse) suppresses glucose-stimulated insulin secretion without affecting circulating basal insulin concentration. Somatostatin-28 (sheep, human rat mouse) also targets to somatostatin receptor subtype 5 (SSTR5) to regulate GLP-1 secretion .

HY-P0276A

GIP, human TFA 1 Publications Verification Gastric Inhibitory Peptide (GIP), human TFA	Insulin Receptor	Metabolic Disease
GIP, human TFA, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP, human TFA acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion .

HY-P3577

[Tyr0] Gastric Inhibitory Peptide (23-42), human	Insulin Receptor	Metabolic Disease
[Tyr0] Gastric Inhibitory Peptide (23-42), human, a glucose-dependent insulinotropic polypeptide (GIP), is a weak inhibitor of gastric acid secretion that also stimulates insulin secretion. [Tyr0] Gastric Inhibitory Peptide (23-42), human can be used in diabetes, obesity research .

HY-128400

4'-Methoxychalcone	PARP	Metabolic Disease Cancer
4'-Methoxychalcone regulates adipocyte differentiation through PPARγ activation. 4'-Methoxychalcone modulates the expression and secretion of various adipokines in adipose tissue that are involved in insulin sensitivity .

HY-P1980

A-71915 TFA	Apoptosis	Metabolic Disease
A-71915 (TFA) is a selective inhibitor of ANP receptor (atrial natriuretic peptide-receptor), induces apoptosis and decreases insulin secretion in RINm5F pancreatic β-cells .

HY-P4785

Acetyl-Amylin (8-37) (human)

Amylin Receptor Metabolic Disease

Acetyl-Amylin (8-37) (human) is a specific amylin antagonist .

Acetyl-Amylin (8-37) (human)	Amylin Receptor	Metabolic Disease
Acetyl-Amylin (8-37) (human) is a specific amylin antagonist .

HY-W030796A

Lactisole	Taste Receptor	Metabolic Disease
Lactisole is a canonical antagonist of sweet taste receptor, selectively targeting to T1R3 subunit, a glucose-sensing receptor. Lactisole inhibits insulin secretion induced by glucose in mouse islets .

HY-P1070

Amylin, amide, human DAP amide, human	Amylin Receptor	Metabolic Disease
Amylin, amide, human, a 37-amino acid polypeptide, is a pancreatic hormone cosecreted with insulin that exerts unique roles in metabolism and glucose homeostasis. Amylin, amide, human inhibits glucagon secretion, delays gastric emptying, and acts as a satiety agent .

HY-P1070A

Amylin, amide, human TFA DAP amide, human TFA	Amylin Receptor	Metabolic Disease
Amylin, amide, human TFA, a 37-amino acid polypeptide, is a pancreatic hormone cosecreted with insulin that exerts unique roles in metabolism and glucose homeostasis. Amylin, amide, human TFA inhibits glucagon secretion, delays gastric emptying, and acts as a satiety agent .

HY-148235

TP-051	Free Fatty Acid Receptor	Metabolic Disease
TP-051 is a potent FFAR1 agonist with an K_i value of 16 nM for human FFAR1. TP-051 can increase insulin secretion in rat insulinoma cells. TP-051 can be used to research type 2 diabetes .

HY-12699

RO5166017 1 Publications Verification	Trace Amine-associated Receptor (TAAR)	Metabolic Disease
RO5166017 is an orally active and species-crosses TAAR1 agonist, with K_i values of 1.9 nM, 2.7 nM, 31 nM and 24 nM for mouse, rat, human and cynomolgus monkey, respectively .

HY-N9536

Cinnamtannin A2	GLP Receptor	Metabolic Disease
Cinnamtannin A2, a tetrameric procyanidin, can increases GLP-1 and insulin secretion in mice. Cinnamtannin A2 could upregulate the expression of corticotrophin releasing hormone. Cinnamtannin A2 exhibits antioxidant, anti-diabetic and nephroprotective effect .

HY-P2541

GIP (1-30) amide, porcine	Insulin Receptor	Metabolic Disease
GIP (1-30) amide, porcine is a full glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with high affinity equal to native GIP(1-42) . GIP (1-30) amide, porcine is a weak inhibitor of gastric acid secretion and potent stimulator of insulin.

HY-W010655

Fasiglifam hemihydrate TAK-875 hemihydrate	Free Fatty Acid Receptor	Metabolic Disease
Fasiglifam (TAK-875) hemihydrate is a potent, selective and orally active GPR40 agonist with EC₅₀ of 72 nM. Fasiglifam enhances glucose-dependent insulin secretion and improves hyperglycemia in type 2 diabetic rats. Fasiglifam can induce liver injury .

HY-P1184

HNGF6A	Reactive Oxygen Species	Cardiovascular Disease Neurological Disease Metabolic Disease
HNGF6A is a humanin analogue. HNGF6A increases glucose-stimulated insulin secretion and glucose metabolism, and has the potential for diabetes research. HNGF6A inhibits of ROS production during oxidative stress. HNGF6A can prevent endothelial dysfunction and atherosclerosis in vivo .

Cat. No.	Product Name	Target	Research Area

HY-P1871A

Amylin (IAPP), feline TFA	Amylin Receptor	Metabolic Disease
Amylin (IAPP), feline TFA is a 37-amino acid polypeptide from feline. Amylin (IAPP), feline TFA is one of the major secretory products of β-cells of the pancreatic islets. Amylin (IAPP), feline TFA is a regulatory peptide, which inhibits insulin and glucagon secretion .

HY-P2534

C-Peptide 2, rat

Peptides Metabolic Disease

C-Peptide 2, rat, 31-amino-acid peptide, is a component of proinsulin. C-Peptide 2, rat can inhibit glucose-induced insulin secretion .

HY-P1257

Xenin-8	Peptides	Metabolic Disease
Xenin-8, a C-terminal octapeptide, is a biologically active fragment of Xenin. Xenin is a 25-amino acid peptide of the neurotensin/xenopsin family. Xenin-8 stimulates basal insulin secretion and potentiates the insulin response to glucose in a dose-dependent manner (EC₅₀=0.16 nM) .

HY-P1257A

Xenin-8 TFA	Peptides	Metabolic Disease
Xenin-8 TFA, a C-terminal octapeptide, is a biologically active fragment of Xenin. Xenin is a 25-amino acid peptide of the neurotensin/xenopsin family. Xenin-8 TFA stimulates basal insulin secretion and potentiates the insulin response to glucose in a dose-dependent manner (EC₅₀=0.16 nM) .

HY-103545

GIP (1-39) Gastric inhibitory peptide (1-39) (porcine)	Peptides	Metabolic Disease
GIP (1-39) (Gastric inhibitory peptide (1-39) (porcine)) is an insulinotropic peptide that stimulats insulin secretion from rat pancreatic islets. GIP (1-39) at 100 nM was able to significantly increase intracellular Ca ²⁺ concentration ([Ca ²⁺]_i), and capable of enhancing exocytosis .

HY-P1871

Amylin (IAPP), feline	Amylin Receptor	Metabolic Disease
Amylin (IAPP), feline is a 37-amino acid polypeptide from feline. Amylin (IAPP), feline is one of the major secretory products of β-cells of the pancreatic islets. Amylin (IAPP), feline is a regulatory peptide, which inhibits insulin and glucagon secretion .

HY-P0150

Glucagon (19-29), human

GCGR Neurological Disease

Glucagon (19-29), human is a potent and efficient inhibitor of insulin secretion.

HY-P0054A

GLP-1(7-36), amide Glucagon-like peptide-1 (GLP-1)(7-36), amide; Human GLP-1 (7-36), amide	GCGR	Metabolic Disease
GLP-1(7-36), amide is a physiological incretin hormone that stimulates insulin secretion.

HY-P2080

GIP (1-30) amide,human	Insulin Receptor	Metabolic Disease
GIP (1-30) amide,human is a glucose-dependent insulinotropic polypeptide (GIP) fragment. GIP is an incretin hormone that stimulates insulin secretion and reduces postprandial glycaemic excursions. GIP (1-30) amide,human dose-dependently promotes insulin secretion over the range 10 ^-9-10 ^-6 M .

HY-P2080B

GIP (1-30) amide,human acetate	Insulin Receptor	Metabolic Disease
GIP (1-30) amide,human acetate is a glucose-dependent insulinotropic polypeptide (GIP) fragment. GIP is an incretin hormone that stimulates insulin secretion and reduces postprandial glycaemic excursions. GIP (1-30) amide,human acetate dose-dependently promotes insulin secretion over the range 10 ^-9-10 ^-6 M .

HY-P0055

GLP-1(7-37)

3 Publications Verification

GCGR Metabolic Disease

GLP-1(7-37) is an intestinal insulinotropic hormone that augments glucose induced insulin secretion.
HY-P0055A

GLP-1(7-37) acetate

3 Publications Verification

GCGR Metabolic Disease

GLP-1(7-37) acetate is an intestinal insulinotropic hormone that augments glucose induced insulin secretion .

HY-P2080C

GIP (1-30)-Myr	Insulin Receptor	Metabolic Disease
GIP (1-30)-Myr is the Myr-modified GIP (1-30), which is a glucose-dependent insulinotropic polypeptide (GIP) fragment. GIP is an incretin hormone that stimulates insulin secretion and reduces postprandial glycaemic excursions. GIP (1-30) dose-dependently promotes insulin secretion over the range 10 ^-9-10 ^-6 M .

HY-P5074

GRPP (human)	GCGR	Metabolic Disease
GRPP (human) is a 30 amino acid Gcg-derived peptide. GRPP (human) causes slight increases in plasma insulin and decreases in plasma glucagon. GRPP (human) does not affect insulin secretion in rat islets .

HY-P0054

GLP-1(7-36), amide acetate Maximum Cited Publications 7 Publications Verification Glucagon-like peptide-1 (GLP-1)(7-36), amide acetate; Human GLP-1 (7-36), amide acetate	GCGR	Metabolic Disease
GLP-1(7-36), amide acetate is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells.

HY-109556

Insulin Detemir	Akt ERK	Metabolic Disease
Insulin Detemir is an artificial insulin, shows effect on controlling blood sugar levels. Insulin Detemir stimulates GLP-1 secretion as a consequence of enhanced Gcg expression by a mechanism involving activation of Akt- and/or extracellular signal-regulated kinase (ERK)-dependent-cat and CREB signaling pathways. Insulin Detemir can be used for type 2 diabetes research .

HY-P10062

Hylambatin	Biochemical Assay Reagents	Metabolic Disease
Hylambatin, a tachykinin, increases both plasma glucose and plasma insulin, whereas the secretion of glucagon was not affected. Hylambatin can be used in diabetes research .

HY-P0054B

GLP-1(7-36), amide TFA Maximum Cited Publications 7 Publications Verification Glucagon-like peptide-1 (GLP-1)(7-36), amide TFA; Human GLP-1 (7-36), amide TFA	GCGR	Metabolic Disease
GLP-1(7-36), amide TFA is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells .

HY-P0276

GIP, human 1 Publications Verification Gastric Inhibitory Peptide (GIP), human	Insulin Receptor	Metabolic Disease
GIP, human, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP, human acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion .

HY-P3954

Somatostatin-28 (sheep, human rat mouse)	Somatostatin Receptor	Metabolic Disease
Somatostatin-28 (sheep, human rat mouse) is a biologically active polypeptide, synthesised in the proximal intestinal epithelial cells. Somatostatin-28 (sheep, human rat mouse) suppresses glucose-stimulated insulin secretion without affecting circulating basal insulin concentration. Somatostatin-28 (sheep, human rat mouse) also targets to somatostatin receptor subtype 5 (SSTR5) to regulate GLP-1 secretion .

HY-P0276A

GIP, human TFA 1 Publications Verification Gastric Inhibitory Peptide (GIP), human TFA	Insulin Receptor	Metabolic Disease
GIP, human TFA, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP, human TFA acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion .

HY-P3577

[Tyr0] Gastric Inhibitory Peptide (23-42), human	Insulin Receptor	Metabolic Disease
[Tyr0] Gastric Inhibitory Peptide (23-42), human, a glucose-dependent insulinotropic polypeptide (GIP), is a weak inhibitor of gastric acid secretion that also stimulates insulin secretion. [Tyr0] Gastric Inhibitory Peptide (23-42), human can be used in diabetes, obesity research .

HY-P1980

A-71915 TFA	Apoptosis	Metabolic Disease
A-71915 (TFA) is a selective inhibitor of ANP receptor (atrial natriuretic peptide-receptor), induces apoptosis and decreases insulin secretion in RINm5F pancreatic β-cells .

HY-P4785

Acetyl-Amylin (8-37) (human)

Amylin Receptor Metabolic Disease

Acetyl-Amylin (8-37) (human) is a specific amylin antagonist .

HY-P1070

Amylin, amide, human DAP amide, human	Amylin Receptor	Metabolic Disease
Amylin, amide, human, a 37-amino acid polypeptide, is a pancreatic hormone cosecreted with insulin that exerts unique roles in metabolism and glucose homeostasis. Amylin, amide, human inhibits glucagon secretion, delays gastric emptying, and acts as a satiety agent .

HY-P1070A

Amylin, amide, human TFA DAP amide, human TFA	Amylin Receptor	Metabolic Disease
Amylin, amide, human TFA, a 37-amino acid polypeptide, is a pancreatic hormone cosecreted with insulin that exerts unique roles in metabolism and glucose homeostasis. Amylin, amide, human TFA inhibits glucagon secretion, delays gastric emptying, and acts as a satiety agent .

HY-P2541

GIP (1-30) amide, porcine	Insulin Receptor	Metabolic Disease
GIP (1-30) amide, porcine is a full glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with high affinity equal to native GIP(1-42) . GIP (1-30) amide, porcine is a weak inhibitor of gastric acid secretion and potent stimulator of insulin.

HY-P1184

HNGF6A	Reactive Oxygen Species	Cardiovascular Disease Neurological Disease Metabolic Disease
HNGF6A is a humanin analogue. HNGF6A increases glucose-stimulated insulin secretion and glucose metabolism, and has the potential for diabetes research. HNGF6A inhibits of ROS production during oxidative stress. HNGF6A can prevent endothelial dysfunction and atherosclerosis in vivo .

HY-P2541A

GIP (1-30) amide, porcine TFA 1 Publications Verification	Insulin Receptor	Metabolic Disease
GIP (1-30) amide, porcine TFA is a full glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with high affinity equal to native GIP(1-42) . GIP (1-30) amide, porcine is a weak inhibitor of gastric acid secretion and potent stimulator of insulin.

HY-P2989

Pyruvate carboxylase	Endogenous Metabolite	Metabolic Disease
Pyruvate carboxylase is a biotin-containing enzyme that catalyzes the HCO3 ⁻ and MgATP dependent carboxylation of pyruvate to form oxaloacetate. Pyruvate carboxylase plays an essential role in controlling whole-body energetics through regulation of gluconeogenesis in the liver, synthesis of fatty acids in adipocytes, and insulin secretion in pancreatic β cells .

HY-P5762A

Phoenixin-14 TFA PNX-14 TFA	GnRH Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Phoenixin-14 (PNX-14) TFA, a BBB-penatrable neuropeptide, has anxiolytic, cardioprotective and neuroprotective effect. Phoenixin-14 TFA can regulate pituitary gonadotrophin secretion by upregulating the GnRH receptor mRNA. Phoenixin-14 TFA stimulates insulin secretion. Phoenixin-14 TFA also protects mice from ischemia/reperfusion (IR) injury. PNX-14 TFA prevents oxidative stress by reducing ROS and increasing GSH .

HY-P1184A

HNGF6A TFA	Reactive Oxygen Species	Cardiovascular Disease Neurological Disease Metabolic Disease
HNGF6A TFA is a humanin analogue. HNGF6A TFA increases glucose-stimulated insulin secretion and glucose metabolism, and has the potential for diabetes research. HNGF6A TFA inhibits of ROS production during oxidative stress. HNGF6A TFA can prevent endothelial dysfunction and atherosclerosis in vivo .

HY-P1072

PHM-27 (human)	CGRP Receptor	Cardiovascular Disease Metabolic Disease
PHM-27 (human) is a human prepro-vasoactive intestinal polypeptide (27 amino acid). PHM-27 (human) is a potent the human calcitonin receptor agonist with an EC₅₀ of 11 nM. PHM-27 (human) efficiently enhances glucose-induced insulin secretion from beta cells by an autocrine mechanism .

HY-P3542

Des His1, Glu8 Exendin-4	GCGR	Metabolic Disease
Des His1, Glu8 Exendin-4 is a potent glucagon-like peptide-1 receptor (GLP-1-R) antagonist. Des His1, Glu8 Exendin-4 improves glucose homeostasis by regulating both insulin secretion and glucose production. Des His1, Glu8 Exendin-4 can be used for the research of type 2 diabetic and gastrointestinal .

HY-P0262

Galantide	Neuropeptide Y Receptor	Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology
Galantide, a non-specific galanin receptor antagonist, is a peptide consisting of fragments of galanin and substance P. Galantide recognizes two classes of galanin binding sites (K_D<0.1 nM and ~6 nM) in the rat hypothalamus. Galantide dose dependently (IC₅₀=1.0 nM) antagonizes the galanin-mediated inhibition of the glucose-induced insulin secretion from mouse pancreatic islets. Galantide appears to bind to a single population of SP receptors (K_D~40 nM) .

HY-P3622

(Ser8)-GLP-1 (7-36) amide, human	GCGR	Metabolic Disease
(Ser8)-GLP-1 (7-36) amide, human is a glucagon-like peptide 1 amide derived from glucagonogen, a cleavage product of the GLP-1 (1-36) amide peptide. (Ser8)-GLP-1 (7-36) amide, human is an entero-insulinotropic hormone that causes glucose-dependent release of insulin from pancreatic β-cells and affects gastrointestinal motility and secretion .

HY-P3019

Urocortin III (human)	CRFR	Cardiovascular Disease Neurological Disease Endocrinology
Urocortin III (human) is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III (human) preferentially binds and activates CRF-R2 and has a discrete central nervous system and peripheral distribution. Urocortin III (human) selectively binds to type 2 CRF receptors with K_i values of 13.5, 21.7, and >100 nM for mCRF2β, rCRF2α, and hCRF1, respectively. Urocortin III (human) mediates somatostatin-dependent negative feedback control of Insulin (human) (HY-P0035) secretion .

HY-P3375

Mazdutide IBI-362; LY-3305677; OXM-3	GCGR GLP Receptor	Metabolic Disease
Mazdutide (IBI-362; LY-3305677) is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide binds human and mouse GCGR (K_i: 17.7 nM and 15.9 nM, respectively) and GLP-1R (K_i: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC₅₀: 5.2 nM). Mazdutide is used in studies of obesity and type 2 diabetes (T2D) .

HY-P5390

GIP, rat	Peptides	Others
GIP, rat is a biological active peptide. (GIP (Glucose-dependent Insulinotropic Polypeptide or also known as Gastric Inhibitory Polypeptide) is a 42-amino acid peptide released by the K cells of the duodenum and jejunum in response to food intake. GIP, together with GLP (Gastric-like Peptide) are members of the hormone peptide family of Incretins which stimulate insulin secretion from pancreatic islet β-cells, and also appears to promote beta cell proliferation and beta cell survival. Recent studies suggest that GIP plays a role in lipid homeostasis and possibly in the pathogenesis of obesity.)

HY-P3375A

Mazdutide TFA IBI-362 TFA; LY-3305677 TFA; OXM-3 TFA	GCGR GLP Receptor	Metabolic Disease
Mazdutide (IBI-362; LY-3305677) TFA is a long-acting synthetic oxyntomodulin analog. Mazdutide is also a co-agonist of glucagon-like peptide (GLP-1R) and glucagon receptor (GCGR). Mazdutide TFA binds human and mouse GCGR (K_i: 17.7 nM and 15.9 nM, respectively) and GLP-1R (K_i: 28.6 nM and 25.1 nM, respectively) and stimulates insulin secretion from mouse islets (EC₅₀: 5.2 nM). Mazdutide TFA is used in studies of obesity and type 2 diabetes (T2D) .

HY-P5390A

GIP, rat TFA	Peptides	Others
GIP, rat TFA is a bioactive peptide of rat origin. (GIP (glucose-dependent insulinotropic polypeptide or also known as gastric inhibitory polypeptide) is a 42-amino acid peptide released by K cells in the duodenum and jejunum in response to food intake. GIP and GLP (gastric-like peptide) are both intestinal A member of the insulinotropic hormone peptide family that stimulates insulin secretion from pancreatic beta cells and appears to also promote beta cell proliferation and beta cell survival. Recent studies suggest that GIP plays a role in lipid homeostasis and may play a role in the pathogenesis of obesity function in the mechanism.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks